Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines
- PMID: 35686125
- PMCID: PMC9171359
- DOI: 10.3389/fimmu.2022.924099
Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines
Keywords: animal model; antigen discovery; immunotherapy; premalignant lesion; tumor microenvironment; vaccine.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
-
Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.Front Immunol. 2022 Jan 27;13:840923. doi: 10.3389/fimmu.2022.840923. eCollection 2022. Front Immunol. 2022. PMID: 35154165 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
